Astrazeneca AB v. Mylan Pharmaceuticals Inc., No. 21-1729 (Fed. Cir. Dec. 8, 2021)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

AstraZeneca AB and AstraZeneca Pharmaceuticals LP (collectively, “AstraZeneca”) sued Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery L.P. (collectively, “Mylan”) for infringement of all claims of U.S. Patent Nos. 7,759,328; 8,143,239; and 8,575,137 (collectively, the “asserted pa- tents”). After claim construction, Mylan stipulated to in- fringement and the district court entered judgment accordingly.